SCHEMBL5072212

SCHEMBL5072212

CCCCn1c(CN(CCc2ccccc2)Cc2cccc(OCC)c2)cnc1-c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
BCHE P06276 9/20 0.49
PPARG P37231 2/20 0.42
PPARA Q07869 2/20 0.42
TSHR P16473 1/20 0.38
HSD11B1 P28845 2/20 0.38
CYP2D6 P10635 2/20 0.38
LTB4R Q15722 1/20 0.37
LTB4R2 Q9NPC1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL648541 0.93 BCHE (0.42) BCHEPPARGPPARATSHRHSD11B1
SCHEMBL5135239 0.93 BCHE (0.47) BCHEPPARGPPARA
SCHEMBL5137333 0.92 BCHE (0.44) BCHEPPARGPPARATSHRHSD11B1
SCHEMBL5135920 0.91 BCHE (0.44) BCHEPPARGPPARATSHRHSD11B1
SCHEMBL5137926 0.89 TSHR (0.41) BCHEPPARGPPARATSHRHSD11B1
SCHEMBL5075074 0.88 TSHR (0.46) BCHETSHRHSD11B1
SCHEMBL5135358 0.86 HSD11B1 (0.42) BCHETSHRHSD11B1
SCHEMBL5072355 0.85 HSD11B1 (0.45) BCHETSHRHSD11B1
SCHEMBL5135801 0.85 PPARG (0.45) BCHEPPARGPPARATSHR
SCHEMBL5134787 0.85 BCHE (0.42) BCHETSHRHSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed